Protara Therapeutics, Inc. (TARA): Price and Financial Metrics

Protara Therapeutics, Inc. (TARA): $3.27

0.13 (+4.14%)

POWR Rating

Component Grades













Add TARA to Watchlist
Sign Up

Industry: Biotech



in industry

TARA Stock Price Chart Interactive Chart >

Price chart for TARA

TARA Price/Volume Stats

Current price $3.27 52-week high $5.80
Prev. close $3.14 52-week low $2.38
Day low $3.18 Volume 3,414
Day high $3.27 Avg. volume 11,356
50-day MA $3.15 Dividend yield N/A
200-day MA $3.30 Market Cap 36.84M

Protara Therapeutics, Inc. (TARA) Company Bio

Protara Therapeutics, Inc. operates as a biotech company. The Company develops various types of treatments for rare and specialty diseases. Protara Therapeutics serves customers in the State of New York.

TARA Latest News Stream

Event/Time News Detail
Loading, please wait...

TARA Latest Social Stream

Loading social stream, please wait...

View Full TARA Social Stream

Latest TARA News From Around the Web

Below are the latest news stories about PROTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate TARA as an investment opportunity.

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the Annual Meeting of the Society of Urologic Oncology being held in San Diego, California from November 30, 2022 through December 2, 2022. The ADVANCED-1 study is evaluating TARA-002, an investiga

Yahoo | December 1, 2022

Protara Therapeutics (TARA) Investor Presentation - Slideshow (NASDAQ:TARA)

The following slide deck was published by Protara Therapeutics, Inc.

Seeking Alpha | November 4, 2022

Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview

- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration, Phase 2 Study of TARA-002 in Lymphatic Malformations Expected to Initiate in 2023 - - Strong Cash, Cash Equivalents and Investments Position of $107.1M as of September 30, 2022 Now Expected to Fund Operations Into 2H2024 - NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: T

Yahoo | November 3, 2022

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | October 24, 2022

The Prognosis For Protara Therapeutics (NASDAQ:TARA)

We put small biopharma concern Protara Therapeutics in the spotlight today for the first time in more than 18 months. Check out our analysis of TARA stock.

Seeking Alpha | October 13, 2022

Read More 'TARA' Stories Here

TARA Price Returns

1-mo 22.01%
3-mo 10.10%
6-mo -1.80%
1-year -37.24%
3-year -89.94%
5-year -96.45%
YTD 22.01%
2022 -60.30%
2021 -72.12%
2020 47.62%
2019 -81.94%
2018 19.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.9508 seconds.